Dapsone
Aczone (dapsone) is a small molecule pharmaceutical. Dapsone was first approved as Dapsone on 1982-01-01. It is used to treat aids-related opportunistic infections, dermatitis herpetiformis, lepromatous leprosy, and relapsing polychondritis in the USA. It is known to target hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Aczone (generic drugs available since 1982-01-01)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| aids-related opportunistic infections | — | D017088 | — |
| dermatitis herpetiformis | — | D003874 | L13.0 |
| lepromatous leprosy | EFO_0001057 | D015440 | A30.5 |
| relapsing polychondritis | EFO_1001148 | D011081 | M94.1 |
Agency Specific
FDA
EMA
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AX: Other anti-acne preparations for topical use in atc
— D10AX05: Dapsone
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04B: Drugs for treatment of lepra
— J04BA: Drugs for treatment of lepra
— J04BA02: Dapsone
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 5 | — | 5 | 13 | — | 23 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 2 | — | 4 | 1 | 2 | 9 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | — | — | 2 | 2 | — | 4 |
| Leprosy | D007918 | EFO_0001054 | A30 | — | — | — | 3 | — | 3 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | 1 | — | 1 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | — | — | 1 | — | 1 |
| Vesiculobullous skin diseases | D012872 | EFO_1000774 | L10-L14 | — | — | — | 1 | — | 1 |
| Leukocytoclastic vasculitis cutaneous | D018366 | EFO_1000974 | D69.0 | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 1 | 2 | 6 | — | 3 | 11 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | 4 | — | 3 | 10 |
| Fever | D005334 | HP_0001945 | R50.9 | — | — | 1 | — | — | 1 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | — | 1 | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | 1 | ||
| Benign mucous membrane pemphigoid | D010390 | L12.1 | — | 1 | 1 | — | — | 1 | |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | 1 | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | — | — | 1 |
| Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 | |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Exanthema | D005076 | R21 | — | 1 | — | — | — | 1 | |
| Pemphigus | D010392 | EFO_1000749 | L10 | — | 1 | — | — | — | 1 |
| Rosacea | D012393 | L71 | — | 1 | — | — | — | 1 | |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | J84.10 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | — | 2 | 2 |
| Prurigo | D011536 | L28.2 | — | — | — | — | 1 | 1 | |
| Leukemia | D007938 | C95 | — | — | — | — | 1 | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | — | — | — | — | 1 | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | — | — | — | 1 | 1 | |
| Lymphoma | D008223 | C85.9 | — | — | — | — | 1 | 1 | |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | — | — | 1 | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DAPSONE |
| INN | dapsone |
| Description | Dapsone is a sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacterium leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy. It has a role as an antimalarial, a leprostatic drug, an antiinfective agent and an anti-inflammatory drug. It is a sulfone and a substituted aniline. It is functionally related to a diphenyl sulfone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 80-08-0 |
| RxCUI | 3108 |
| ChEMBL ID | CHEMBL1043 |
| ChEBI ID | 4325 |
| PubChem CID | 2955 |
| DrugBank | DB00250 |
| UNII ID | 8W5C518302 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
Organism
Plasmodium falciparum 3D7
Gene name
Gene synonyms
NCBI Gene ID
Protein name
hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase
Protein synonyms
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Aczone - Allergan
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Aczone - Warner Chilcott
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,492 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,688 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more